HPGD and PRDM1

Data Source:
BioGRID (proximity labelling technology)

		HPGD	PRDM1
Description		15-hydroxyprostaglandin dehydrogenase	PR/SET domain 1
Image
GO Annotations	Cellular Component	Nucleoplasm Cytoplasm Cytosol Basolateral Plasma Membrane Extracellular Exosome	Nucleus Nucleoplasm Cytoplasm
	Molecular Function	Prostaglandin E Receptor Activity 15-hydroxyprostaglandin Dehydrogenase (NAD+) Activity Oxidoreductase Activity, Acting On The CH-OH Group Of Donors, NAD Or NADP As Acceptor Identical Protein Binding NAD Binding NAD+ Binding	RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Repressor Activity, RNA Polymerase II-specific DNA-binding Transcription Factor Activity Protein Binding Methyltransferase Activity Histone Deacetylase Binding Metal Ion Binding Sequence-specific Double-stranded DNA Binding Promoter-specific Chromatin Binding
	Biological Process	Kidney Development Prostaglandin Metabolic Process Transforming Growth Factor Beta Receptor Signaling Pathway Female Pregnancy Parturition Lipoxygenase Pathway Ovulation Response To Estradiol Response To Lipopolysaccharide Long-chain Fatty Acid Biosynthetic Process Positive Regulation Of Apoptotic Process Response To Ethanol Negative Regulation Of Cell Cycle Thrombin-activated Receptor Signaling Pathway Ductus Arteriosus Closure Positive Regulation Of Vascular Associated Smooth Muscle Cell Proliferation Regulation Of Prostaglandin Catabolic Process Lipoxin Biosynthetic Process	Negative Regulation Of Transcription By RNA Polymerase II Adaptive Immune Response Regulation Of Transcription By RNA Polymerase II Regulation Of Gene Expression Methylation Regulation Of Natural Killer Cell Differentiation Regulation Of Extrathymic T Cell Differentiation Innate Immune Response Cell Fate Commitment Regulation Of NK T Cell Differentiation
Pathways		Synthesis of Lipoxins (LX) Synthesis of Prostaglandins (PG) and Thromboxanes (TX) Biosynthesis of D-series resolvins Biosynthesis of E-series 18(S)-resolvins	Regulation of TP53 Expression
Drugs		NADH
Diseases		Primary hypertrophic osteoarthropathy (PHO)
GWAS		Alcohol dependence ( 26365420) Metabolite levels ( 23823483) Venous thromboembolism adjusted for sickle cell variant rs77121243-T ( 28203683)	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) ( 23648065) Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) ( 23648065) Carboplatin disposition in epthelial ovarian cancer ( 29367611) Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) ( 26974007) Crohn's disease ( 21102463) Diastolic blood pressure ( 30224653) Monobrow ( 27182965) Multiple myeloma ( 27363682) Response to (pegylated) interferon in HBeAG-positive hepatitis B ( 30715261) SjÃ¶gren's syndrome ( 24097067) Systemic lupus erythematosus ( 27399966 23273568 26502338 28714469 19838193 19838195) Systemic sclerosis ( 28314753) Triglyceride levels ( 32203549)
Interacting Genes		1 interacting genes: APP	10 interacting genes: ATXN1 H1-1 H3C15 IKZF3 IRF4 KDM1A PIAS1 TLE1 TLE2 TLE5
Entrez ID		3248	639
HPRD ID		03406	04572
Ensembl ID		ENSG00000164120	ENSG00000057657
Uniprot IDs		P15428	A0A3B3IU23 B4DW27 O75626 Q5T4E8
PDB IDs		2GDZ	3DAL
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?